← Oncology Approval Tracker

FDA DECISION ·

Iwilfin

eflornithine · USWM

FDA approvalNew therapyNeuroblastoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

To lower relapse risk in adults and children with high-risk neuroblastoma who achieved at least a partial response after multiagent, multimodality treatment that included anti-GD2 immunotherapy.

LAMPGEN ANALYSIS

Why it matters

The approved use targets relapse risk after a response to intensive treatment.

What research teams should watch

Document prior anti-GD2 exposure and best response when assessing eligibility.

PRIMARY RECORDS

Sources